ARCTURUS THERAPEUTICS HOLDINGS INC. Increase (Decrease) in Accrued Liabilities
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) reported Increase (Decrease) in Accrued Liabilities of -$1.06 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-06
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $173.00K.
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$1.23M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $4.45M, a 32.09% decline year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was -$5.42M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase (decrease) in accrued liabilities for fiscal 2025 was -$15.27M, a 357.33% decline from fiscal 2024.
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase (decrease) in accrued liabilities for fiscal 2024 was $5.93M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase (decrease) in accrued liabilities for fiscal 2023 was -$588.00K, a 106.23% decline from fiscal 2022.
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase (decrease) in accrued liabilities for fiscal 2022 was $9.44M, a 128.42% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month | Increase (Decrease) in Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $173.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.06M 10-Q · filed 2026-08-06 | $3.39M derived: sum of 3 quarters · filed 2026-08-06 | -$2.02M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | -$1.23M 10-Q · filed 2026-05-07 | $3.22M derived: sum of 2 quarters · filed 2026-05-07 | -$2.20M derived: sum of 3 quarters · filed 2026-05-07 | -$8.26M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $4.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$964.00K derived: sum of 2 quarters · filed 2026-03-03 | -$7.02M derived: sum of 3 quarters · filed 2026-08-06 | -$15.27M 10-K · filed 2026-03-03 | ||
| 2025-09-30 | -$5.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$11.47M derived: sum of 2 quarters · filed 2026-08-06 | -$19.72M 10-Q · filed 2025-11-12 | -$13.16M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | -$6.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$14.30M 10-Q · filed 2026-08-06 | -$7.74M derived: sum of 3 quarters · filed 2026-08-06 | -$11.00M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | -$8.24M 10-Q · filed 2026-05-07 | -$1.69M derived: sum of 2 quarters · filed 2026-05-07 | -$4.94M derived: sum of 3 quarters · filed 2026-05-07 | -$4.65M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $6.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $3.30M derived: sum of 2 quarters · filed 2026-03-03 | $3.59M derived: sum of 3 quarters · filed 2026-03-03 | $5.93M 10-K · filed 2026-03-03 | ||
| 2024-09-30 | -$3.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$2.96M derived: sum of 2 quarters · filed 2025-11-12 | -$625.00K 10-Q · filed 2025-11-12 | $2.22M derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2024-06-30 | $292.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $2.63M 10-Q · filed 2025-08-11 | $5.48M derived: sum of 3 quarters · filed 2026-03-03 | $5.03M derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2024-03-31 | $2.34M 10-Q · filed 2025-05-12 | $5.19M derived: sum of 2 quarters · filed 2026-03-03 | $4.73M derived: sum of 3 quarters · filed 2026-03-03 | $765.00K derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2023-12-31 | $2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $2.40M derived: sum of 2 quarters · filed 2026-03-03 | -$1.57M derived: sum of 3 quarters · filed 2026-03-03 | -$588.00K 10-K · filed 2026-03-03 | ||
| 2023-09-30 | -$454.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$4.42M derived: sum of 2 quarters · filed 2024-11-07 | -$3.44M 10-Q · filed 2024-11-07 | $3.99M derived: sum of 4 quarters · filed 2025-03-06 | ||
| 2023-06-30 | -$3.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | -$2.98M 10-Q · filed 2024-08-05 | $4.45M derived: sum of 3 quarters · filed 2025-03-06 | $599.00K derived: sum of 4 quarters · filed 2025-03-06 | ||
| 2023-03-31 | $986.00K 10-Q · filed 2024-05-08 | $8.41M derived: sum of 2 quarters · filed 2025-03-06 | $4.57M derived: sum of 3 quarters · filed 2025-03-06 | $13.98M derived: sum of 4 quarters · filed 2025-03-06 | ||
| 2022-12-31 | $7.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $3.58M derived: sum of 2 quarters · filed 2025-03-06 | $13.00M derived: sum of 3 quarters · filed 2025-03-06 | $9.44M 10-K · filed 2025-03-06 | ||
| 2022-09-30 | -$3.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $5.57M derived: sum of 2 quarters · filed 2023-11-14 | $2.02M 10-Q · filed 2023-11-14 | -$7.42M derived: sum of 4 quarters · filed 2024-03-14 | ||
| 2022-06-30 | $9.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $5.86M 10-Q · filed 2023-08-07 | -$3.57M derived: sum of 3 quarters · filed 2024-03-14 | -$7.73M derived: sum of 4 quarters · filed 2024-03-14 | ||
| 2022-03-31 | -$3.55M 10-Q · filed 2023-05-09 | -$4.00M 10-Q · filed 2022-05-09 | -$12.99M derived: sum of 2 quarters · filed 2024-03-14 | -$17.15M derived: sum of 3 quarters · filed 2024-03-14 | -$6.56M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-12-31 | -$9.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$13.59M derived: sum of 2 quarters · filed 2024-03-14 | -$3.01M derived: sum of 3 quarters · filed 2024-03-14 | $4.13M 10-K · filed 2024-03-14 | $2.78M 10-K · filed 2022-03-01 | |
| 2021-09-30 | -$4.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $6.43M derived: sum of 2 quarters · filed 2022-11-09 | $13.57M 10-Q · filed 2022-11-09 | $17.55M derived: sum of 4 quarters · filed 2022-11-09 | ||
| 2021-06-30 | $10.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $17.73M 10-Q · filed 2022-08-09 | $21.71M derived: sum of 3 quarters · filed 2022-08-09 | $25.43M derived: sum of 4 quarters · filed 2022-08-09 | ||
| 2021-03-31 | $7.14M 10-Q · filed 2022-05-09 | $11.13M derived: sum of 2 quarters · filed 2022-05-09 | $14.84M derived: sum of 3 quarters · filed 2022-05-09 | $16.72M derived: sum of 4 quarters · filed 2022-05-09 | ||
| 2020-12-31 | $3.98M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $7.70M derived: sum of 2 quarters · filed 2022-03-01 | $9.57M derived: sum of 3 quarters · filed 2022-03-01 | $11.32M 10-K · filed 2022-03-01 | ||
| 2020-09-30 | $3.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $5.59M derived: sum of 2 quarters · filed 2021-11-09 | $7.33M 10-Q · filed 2021-11-09 | $7.58M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-06-30 | $1.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $3.62M 10-Q · filed 2021-08-10 | $3.86M derived: sum of 3 quarters · filed 2022-03-01 | $6.83M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-03-31 | $1.75M 10-Q · filed 2021-05-10 | $1.99M derived: sum of 2 quarters · filed 2022-03-01 | $4.96M derived: sum of 3 quarters · filed 2022-03-01 | $5.48M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2019-12-31 | $243.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $3.21M derived: sum of 2 quarters · filed 2022-03-01 | $3.73M derived: sum of 3 quarters · filed 2022-03-01 | $1.68M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $2.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $3.49M derived: sum of 2 quarters · filed 2020-11-09 | $1.43M 10-Q · filed 2020-11-09 | $3.11M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2019-06-30 | $524.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$1.54M 10-Q · filed 2020-08-10 | $142.00K derived: sum of 3 quarters · filed 2021-03-01 | -$1.61M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2019-03-31 | -$2.06M 10-Q · filed 2020-05-08 | -$382.00K derived: sum of 2 quarters · filed 2021-03-01 | -$2.14M derived: sum of 3 quarters · filed 2021-03-01 | |||
| 2018-12-31 | $1.68M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$77.00K derived: sum of 2 quarters · filed 2021-03-01 | $1.69M 10-K · filed 2021-03-01 | |||
| 2018-09-30 | -$1.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $9.00K 10-Q · filed 2019-11-08 | ||||
| 2018-06-30 | $1.76M 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |